Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | London | Healthcare | Biotechnology & Medical Research | £37.06B | 67.1x | GBX 51,283.85 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
arGEN X BV | London | Healthcare | Biotechnology & Medical Research | £30.95B | -947.3x | -11.4 | GBX 50,968.69 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | London | Healthcare | Biotechnology & Medical Research | £10.91B | 12.6x | 0.14 | GBX 17,156.10 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | London | Healthcare | Biotechnology & Medical Research | £6.83B | 103.9x | -1.36 | GBX 3,161.32 | -12.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | London | Healthcare | Biotechnology & Medical Research | £6.15B | -47.3x | 3.06 | GBX 8,711.30 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech L | London | Healthcare | Biotechnology & Medical Research | £1.82B | 16.6x | 0.12 | GBX 3,333.54 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Geron Corp | London | Healthcare | Biotechnology & Medical Research | £1.25B | -8.2x | -1.43 | GBX 211 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | London | Healthcare | Biotechnology & Medical Research | £1.18B | 149.7x | -2.03 | GBX 1,790 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.6% Upside | Upgrade to Pro+ | |
Intellia Therapeutics | London | Healthcare | Biotechnology & Medical Research | £927.73M | -2.1x | 1.2 | GBX 943.40 | -51.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oxford BioMedica | London | Healthcare | Biotechnology & Medical Research | £410.12M | -2.8x | 0.02 | GBX 387 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.6% Upside | Upgrade to Pro+ | |
PureTech Health | London | Healthcare | Biotechnology & Medical Research | £348.60M | -6.1x | 0.07 | GBX 145.60 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Allergy Therapeutics | London | Healthcare | Biotechnology & Medical Research | £306.96M | -5.9x | -0.09 | GBX 6.44 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Verastem | London | Healthcare | Biotechnology & Medical Research | £210.55M | -1.9x | -0.14 | GBX 473.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faron Pharmaceuticals Oy | London | Healthcare | Biotechnology & Medical Research | £176.29M | -4.5x | -1.13 | GBX 168.50 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bioventix | London | Healthcare | Biotechnology & Medical Research | £152.67M | 18.9x | -5.41 | GBX 2,925 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Avacta Group | London | Healthcare | Biotechnology & Medical Research | £151.01M | -4.8x | -0.15 | GBX 41.27 | 5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
4BASEBIO UK SOCIETAS | London | Healthcare | Biotechnology & Medical Research | £143.42M | -15.9x | 0.27 | GBX 1,120 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hvivo | London | Healthcare | Biotechnology & Medical Research | £120.90M | 6.8x | 0.01 | GBX 17.86 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Editas Medicine | London | Healthcare | Biotechnology & Medical Research | £113.28M | -0.7x | -0.12 | GBX 130.09 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scancell | London | Healthcare | Biotechnology & Medical Research | £92.45M | -5.3x | 0.22 | GBX 9 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Corbus Pharmaceuticals Holdings | London | Healthcare | Biotechnology & Medical Research | £78.78M | -1.9x | -0.04 | GBX 647.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Transgene | London | Healthcare | Biotechnology & Medical Research | £78.30M | -3.2x | -0.12 | GBX 59.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm Advanced Comm | London | Healthcare | Biotechnology & Medical Research | £76.70M | -221.3x | 1.45 | GBX 17.57 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotec Pharmacon | London | Healthcare | Biotechnology & Medical Research | £72.52M | 133.3x | -2.12 | GBX 146.03 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Adverum Biotechnologies | London | Healthcare | Biotechnology & Medical Research | £68.65M | -0.8x | -0.02 | GBX 359.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Inovio Pharmaceuticals | London | Healthcare | Biotechnology & Medical Research | £62.12M | -0.5x | -0.02 | GBX 172.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nordic Nanovector | London | Healthcare | Biotechnology & Medical Research | £53.42M | -42.9x | GBX 17.20 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SkinBioTherapeutics | London | Healthcare | Biotechnology & Medical Research | £46.26M | -13.4x | -1.46 | GBX 20.25 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OncoCyte | London | Healthcare | Biotechnology & Medical Research | £44.94M | -0.7x | -0.02 | GBX 219.84 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Futura | London | Healthcare | Biotechnology & Medical Research | £44.66M | -12x | -0.39 | GBX 14.70 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics Holding | London | Healthcare | Biotechnology & Medical Research | £36.30M | -0.4x | GBX 289.49 | 105% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Novacyt SA | London | Healthcare | Biotechnology & Medical Research | £34.29M | -0.9x | 0.02 | GBX 48.47 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Shield Therapeutics | London | Healthcare | Biotechnology & Medical Research | £29.01M | -1x | -0.02 | GBX 3.71 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synairgen | London | Healthcare | Biotechnology & Medical Research | £26.13M | -0.7x | -0.12 | GBX 2.37 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Poolbeg Pharma | London | Healthcare | Biotechnology & Medical Research | £24.50M | -11.1x | -0.55 | GBX 4.86 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sareum | London | Healthcare | Biotechnology & Medical Research | £22.49M | -4.2x | -0.72 | GBX 18 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ananda Developments | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £21.71M | -1.8x | 0 | GBX 0.49 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Palatin Technologies | London | Healthcare | Biotechnology & Medical Research | £20.94M | -0.7x | 0.12 | GBX 82.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arecor Therapeutics | London | Healthcare | Biotechnology & Medical Research | £20.58M | -2.7x | -0.27 | GBX 52.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuPharma | London | Healthcare | Biotechnology & Medical Research | £19.32M | -8.3x | -0.2 | GBX 4.64 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Optibiotix Health | London | Healthcare | Biotechnology & Medical Research | £15.79M | -5x | -0.06 | GBX 16.12 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Phaxiam Therapeutics | London | Healthcare | Biotechnology & Medical Research | £15.38M | -0.4x | GBX 157.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
MEI Pharma | London | Healthcare | Biotechnology & Medical Research | £14.24M | -0.5x | 0 | GBX 221.86 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Celyad | London | Healthcare | Biotechnology & Medical Research | £14.09M | -1.9x | -0.03 | GBX 66.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incanthera | Aquis Exchange | Healthcare | Biotechnology & Medical Research | £13.74M | -4.8x | -0.01 | GBX 10.75 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Synlogic | London | Healthcare | Biotechnology & Medical Research | £13.24M | -0.4x | -0.01 | GBX 105.93 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IXICO | London | Healthcare | Biotechnology & Medical Research | £11.12M | -2.9x | 0.08 | GBX 12 | -4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OpGen | London | Healthcare | Biotechnology & Medical Research | £10.87M | -0.3x | -0.02 | GBX 100.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hemogenyx Pharma | London | Healthcare | Biotechnology & Medical Research | £10.60M | -1.7x | -0.06 | GBX 302.80 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Aeterna Zentaris | London | Healthcare | Biotechnology & Medical Research | £8.16M | -0.2x | 0.02 | GBX 237 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |